DUX4 and neuromuscular disease: For example, a strategy targeting DUX4 mRNA using an antisense oligonucleotide will suffer of the same limitations as in other neuromuscular diseases, such as the low intracellular delivery, distribution, long term toxicity, or potential immunogenicity that may vary according to the type of chemical modifications introduced on the nucleic acids (for review see [78]).